



FOR IMMEDIATE RELEASE

February 6, 2026

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito
	Representative Corporate
	Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Teruyuki Masaka Vice President, Corporate Communications Phone +81-3-3817-5120

Revenue of LEQEMBI® (Preliminary Basis)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI®" (generic name: lecanemab) was JPY 61.8 billion for the cumulative period of the third quarter of fiscal year 2025 (April 1, 2025 – December 31, 2025). By major markets, revenue came to JPY 31.2 billion in the United States, JPY 17.9 billion in Japan, and JPY 8.3 billion in China.

This information is being disclosed in conjunction with today's announcement of the financial results for the full year 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the third quarter of fiscal year 2025, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for February 9, 2026.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
